Key Highlights
- Management lowered full-year 2026 Revenue guidance to USD 13.5 million to USD 14.5 million from a prior range of USD 16 million to USD 18 million, citing funding constraints and longer purchasing timelines.
- Third-quarter revenue was USD 3.981 million, down 3% from USD 4.121 million a year earlier but up from USD 3.1 million in the second quarter on management's figures.
- The net loss narrowed 25% to USD 13.7 million from USD 18.2 million, as operating expenses fell 23% to USD 16.5 million and Research and Development dropped 40%.
- Cash, cash equivalents and investments totaled USD 198.1 million at September 30, 2026, while nine-month cash used in operations was USD 34.5 million.
Guidance Cut Follows Longer Sales Cycles and an Activist Fight
Seer filed its Quarterly Report on November 10, 2026, and held its call the same day. On the call, management lowered 2026 revenue guidance to USD 13.5 million to USD 14.5 million from USD 16 million to USD 18 million. It named two causes: funding constraints in academic and government research that extended sales cycles, and customer uncertainty during an activist campaign and subsequent Acquisition proposals. Management said several late-stage opportunities are now expected to close later than planned. On October 29, a Special Committee concluded its review and the company said it will remain independent. Nine-month revenue of USD 9.9 million is 20% below USD 12.4 million a year earlier, so the revised range implies fourth-quarter revenue of about USD 3.6 million to USD 4.6 million (calculated).
Product Revenue Flat, Service Up, Related-Party Sales Down
Seer (NASDAQ:SEER) sells the Proteograph Product Suite, which combines engineered nanoparticle consumables, an automation instrument and software to let researchers measure thousands of proteins in blood samples with mass spectrometry. In the third quarter, product revenue was USD 2.76 million, essentially flat, service revenue rose 17% to USD 1.06 million, and related-party revenue fell 70% to USD 0.09 million. Gross Profit fell 11% to USD 1.9 million, a gross Margin of 47% on management's figure, down 130 basis points from the second quarter. Management said it still sees long-term gross margin of 70% to 75% at scale, a target and not a forecast for any near-term quarter.
Lower Spending and a USD 198.1 Million Cash Cushion
Research and development expense fell to USD 6.4 million from USD 10.8 million on lower compensation, stock-based pay, laboratory and professional costs. Selling, general and administrative expense eased 5% to USD 10.1 million, with higher professional services of USD 2.5 million offsetting lower compensation. Interest income slipped to USD 2.0 million from USD 2.8 million on lower rates. Nine-month net loss was USD 47.5 million against USD 57.6 million. The company said it does not expect positive Operating Cash Flow for the foreseeable future, and its accumulated Deficit was USD 513.4 million. It bought back about 61,000 shares in the quarter at an average USD 1.64, with about USD 25 million of authorization left.
Where Things Stand
The cut reflects slower customer conversion, not a collapse in activity. Seer (NASDAQ:SEER) trimmed its 2026 revenue range by USD 2.5 million at the low end and USD 3.5 million at the high end (calculated), while quarterly revenue edged down 3%. Costs are falling, losses are narrowing and the Balance Sheet holds USD 198.1 million. Against that, revenue is small relative to spending, and the guidance now depends on late-stage deals closing. Next markers are fourth-quarter shipments, whether academic funding recovers and whether biopharma consumable orders keep repeating.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...